Stocks analysis

AAPL vs ABBV Stock Comparison

Scores Breakdown

Metric AAPL ABBV
📈 Growth 22/30 26/30
💰 Profitability 14/20 18/20
🏦 Financial Health 18/20 6/20
💵 Valuation 15/20 12/20
⚠️ Risk (lower is better) 6/10 8/10
Overall Score 73/100 64/100

Side-by-Side Summaries

AAPL Analysis ABBV Analysis

📈 Growth & Financial Trajectory

Over 8 quarters Apple progressed from Revenues of $94.93B in 2024Q4 to $109.42B in 2026Q3, with a notable mid-period spike to $143.76B in 2025Q3. Net income rose from $14.74B to $29.79B, signaling solid earnings growth despite volatility in quarterly mix. The sequence ends with higher absolute revenue and sustained profitability versus the start, though the pace is uneven.

💰 Margins & Cash Flow

Gross margin fluctuated: early quarters near the 60%+ range, dipping to the mid-40s–50s during 2025Q3, then stabilizing around the low- to mid-50% range in 2026. Operating margin followed suit, with positive cash flow from operations in most quarters and generally positive free cash flow despite variable investing cash flow. Net cash from operating activities remained positive across the window; financing cash flows were typically negative.

🛡️ Balance Sheet & Liquidity

Assets stay robust at roughly $330B–$379B, with liabilities around $264B–$291B and equity in the $56B–$88B range, indicating a solid balance sheet. Current assets exceed current liabilities in most periods, supporting liquidity, while long-term debt remains modest relative to earnings power.

⚠️ Key Drivers & Risks

  • Drivers: iPhone and Services acceleration; broad ecosystem and high-margin software/services expansion.
  • Risks: demand cyclicality and competitive/margin pressure; regulatory/valuation sensitivity to hardware cycles.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.